A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Abemaciclib|DRUG: Standard Adjuvant ET|DRUG: Placebo
Sponsor: Eli Lilly and Company